Company Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders.
It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer.
The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | May 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Howard Robin |
Contact Details
Address: 455 Mission Bay Boulevard South San Francisco, California 94158 United States | |
| Phone | 415 482 5300 |
| Website | nektar.com |
Stock Details
| Ticker Symbol | NKTR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000906709 |
| CUSIP Number | 640268108 |
| ISIN Number | US6402681083 |
| Employer ID | 94-3134940 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard W. Robin | Chief Executive Officer, President and Director |
| Sandra A. Gardiner | Chief Financial Officer |
| Mark A. Wilson J.D. | Senior Vice President, Chief Legal Officer and Secretary |
| Dr. Jonathan Zalevsky Ph.D. | Chief Research and Development Officer |
| Vivian Wu | Director of Investor Relations and Corporate Affairs |
| Robert Bacci | Senior Vice President of Human Resources and Facilities Operations |
| Jennifer Ruddock | Chief Business Officer |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 144 | Filing |
| Dec 18, 2024 | 144 | Filing |
| Dec 17, 2024 | 144 | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 144 | Filing |
| Nov 19, 2024 | 144 | Filing |
| Nov 19, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |